Qinjiu Powder Veterinary Grade API is a dried, standardised extract prepared from the root of Gentiana macrophylla Pall. and supplied as a controlled botanical active for incorporation into tablets, capsules, dry powders, oral granules, medicated feed premixes, and oral or injectable solutions. The term “veterinary grade API” specifies that the material is manufactured under a veterinary drug GMP framework and released against a certificate of analysis, not as a feed additive, food ingredient, or cosmetic extract. Model nomenclature is vendor-defined rather than pharmacopoeial. A standardised grade containing 5.0% w/w gentiopicroside may be assigned a code such as QJ-V-API-5.0; the suffix indicates the declared marker strength, not a compendial designation. Other strengths are identified by the same prefix with the corresponding assay value. Because this exact veterinary-grade configuration is not described in all regional pharmacopoeias, the relevant baseline remains the Chinese Veterinary Pharmacopoeia 2020 monograph for Gentianae Macrophyllae Radix, supplemented by general chapters for botanical extracts.

Because the active fraction comprises secoiridoid glycosides, gentiopicroside is used as the principal marker rather than total herb weight. Standardisation to a declared gentiopicroside content by HPLC separates the product from non-standardised root powder and from simple mechanical milling of whole herb. The marker is expressed as C₁₆H₂₀O₉ on the dried basis, with retention-time identity confirmed against a reference standard. Total secoiridoid glycosides may be reported as a secondary marker when the target-species submission requires broader chemical characterisation. For non-sterile oral and feed premix applications, standardised grades are commonly supplied at 5.0% w/w, while lower or higher grades are produced by adjusting the extraction ratio. The exact lot value is declared on the certificate of analysis and should not be inferred from the product code alone.

What Pharmacopoeial Markers Define This Veterinary API?

Identity is established by thin-layer chromatography and HPLC retention-time matching against gentiopicroside reference standard. In the Chinese Veterinary Pharmacopoeia 2020 raw-herb monograph, the assay is performed by HPLC with UV detection; when applied to a concentrated extract, the criterion is adjusted for loss on drying and extractable matter. The product is therefore defined by marker concentration per unit mass rather than by foreign-matter absence or colour alone. Release specifications for the non-sterile oral and premix grade include identification, marker assay, moisture, total ash, acid-insoluble ash, heavy metals, microbial limits, residual solvents, and particle-size distribution. Injectable-grade powder requires additional bacterial endotoxin and insoluble particulate evaluation because the dry powder is not sterile by default.

Assay of the API is performed by HPLC with a C18 column, 5 µm packing, 250 mm × 4.6 mm, mobile phase acetonitrile-water acidified with 0.1% phosphoric acid, and UV detection at 254 nm or 270 nm. System suitability typically requires a tailing factor ≤ 2.0 and theoretical plates ≥ 3000 for the gentiopicroside peak. Extraction solvent selection should be documented because secoiridoid glycosides are heat-sensitive; direct reflux in acidified methanol can overestimate marker content if artefact degradation is not excluded.

These criteria are a representative procurement profile, not a universal pharmacopoeial monograph. Manufacturers of injectable dosage forms must establish product-specific acceptance limits for bacterial endotoxins and subvisible particles. For oral tablets and capsules, the particle-size specification is usually tightened to a D₉₀ of less than 200 µm to reduce content-uniformity failures during direct compression. The powder should not be sterilised by autoclaving unless forced-degradation data demonstrate marker stability; the preferred approach for injectables is dissolution followed by 0.22 µm filtration.

Particle-size reduction follows compendial sieve cuts rather than visual granulation.

Processing behaviour on production-scale equipment is governed by particle-size distribution, surface moisture, and bulk-density variation more than by marker content alone. The powder is moderately hygroscopic; at relative humidity above 60%, pre-drying at 50–55 °C for 2–4 hours is required before weighing or direct compression to prevent sticking and erratic flow. Flow consistency is assessed by Carr Index and Hausner ratio rather than by nominal mesh number alone. A Carr Index above 25 indicates the need for 0.5%–1.0% colloidal silicon dioxide or equivalent glidant, while a Hausner ratio above 1.35 typically requires roller compaction or wet granulation instead of direct compression.

In a high-shear mixer with impeller speed of 200–300 m/min, wet granulation endpoint is judged by impeller torque or power consumption rather than visual appearance. The liquid-to-solid ratio is normally held at 0.08–0.12 for a 25% active granulation; exceeding 0.14 may produce hard granules that fail to release the marker under USP <711> Apparatus II at 50 rpm. Granule milling to 20–60 mesh with fines below 120 mesh limited to 15%–20% reduces tablet capping. For twin-screw wet granulation, feed rates of 20–30 kg/h with gravimetric liquid addition are typical; torque oscillations above 10% of the mean signal indicate non-uniform binder distribution and require a kneading-block configuration change. Roller compaction with ribbed rolls at 4–6 kN/cm roll force produces ribbons of 0.9–1.1 g/mL density; lower force creates friable ribbons that lead to oversized granules and poor tablet weight consistency.

Tablets are prepared by wet granulation or direct compression. The API is blended with microcrystalline cellulose and lactose monohydrate; the wet mass is granulated with povidone or hypromellose and compressed to hardness of 6–10 kp. Content uniformity is evaluated by USP <905>; an acceptance value ≤ 15.0 for 10 dosage units is the standard threshold. Capsule filling is feasible when the Carr Index is below 20; otherwise, the powder is densified by slugging or roller compaction. On a dosator-type capsule machine, low bulk density below 0.35 g/mL can cause underweight fills because tamping force is poorly transmitted through the powder bed; adjustment of tamping stations and addition of 0.5% magnesium stearate may improve fill weight but can delay dissolution if blending time exceeds 5 minutes.

For oral solutions, the powder is dispersed in purified water at 40–50 °C under high-shear mixing and passed through 0.45 µm filtration to remove insoluble plant fibres. For injectable solutions, aseptic processing is mandatory; the solution is passed through 0.22 µm sterilising-grade polyethersulfone membrane and filled under nitrogen to reduce oxidative degradation. For granules and powders, wet granulation with 2% w/w hypromellose solution or dry granulation by roller compactor is used to improve flow and reduce dust. For feed premix, the API is diluted stepwise with corn starch, dextrose, or calcium carbonate; the final mix should achieve a coefficient of variation below 10% for the active marker when sampled according to ISO 6497.

Microbial, Heavy-Metal, and Residual-Solvent Control

Microbial quality is a release criterion rather than a post-process corrective. Since raw root may enter the facility with soil-borne microbial loads, extraction and concentration do not automatically reduce spores; the powder is therefore produced with controlled thermal processing or irradiation only if the target-species regulatory dossier permits. Heavy-metal limits are set according to the target animal and duration of exposure. The representative limits in the table correspond to long-term oral administration in food-producing species but may need to be tightened for neonatal animals or injectable solutions. Residual solvent control follows VICH GL18; ethanol is the most common extraction solvent and is typically reduced to less than 5000 ppm in the finished powder. For injectable grades, the powder is dissolved and sterile-filtered at 0.22 µm rather than steam-sterilised, because autoclaving can degrade gentiopicroside and increase colour intensity.

Stability of the dry powder under VICH GL3 long-term conditions at 25 °C/60% RH and accelerated conditions at 40 °C/75% RH should be established for the specific packaging configuration. Hygroscopic uptake above 5% moisture can promote caking and microbial growth; the moisture-content specification therefore functions as both a chemical and a microbiological control. Water activity is generally maintained below 0.60 for non-sterile botanical APIs, although this parameter is not a surrogate for total aerobic microbial count. Because botanical material can carry aflatoxins, aflatoxin B₁ is additionally controlled according to national or regional feed limits where required.

When Qinjiu Powder Is Substituted for Raw Herb in Injectable Manufacture

Substitution of raw herb with standardised powder changes the manufacturing control logic. Raw herb requires decoction or percolation at the compounding facility, with variability related to particle size, water hardness, temperature, and time. Qinjiu Powder Veterinary Grade API transfers that variability to the extract manufacturer, but introduces solubility and filtration burden at the finished-product site. Injectable solution manufacture requires the powder to dissolve without visible flocculate; high-speed dispersion at 10,000 rpm is commonly used, followed by pH adjustment to 4.5–6.5. Gentiopicroside is stable in weakly acidic aqueous solution but degrades more rapidly above pH 7.5 and under strong oxidising conditions; therefore, combination with benzyl alcohol-preserved solutions requires forced-degradation verification. Published data for this specific veterinary API in injectable matrices are limited; pilot-scale filtration studies using the actual lot are therefore recommended before defining the master batch record.

Incompatibility is observed with strong acids, strong bases, and oxidising agents; the secoiridoid glycosides may undergo opening of the lactone ring under alkaline conditions, which reduces marker assay and increases bitter taste variability. The powder should be stored in sealed double polyethylene bags inside fibre drums, in a dry warehouse below 25 °C and RH below 60%. Once opened, the material should be used within 30 days or resealed with desiccant. For markets requiring veterinary drug registration, the API should be described in the veterinary medicinal product dossier by extraction solvent, extraction ratio, marker assay, and residual solvent profile; a raw-herb monograph is not sufficient for an injectable or premix product. The powder should not be combined with amine-based microbial inhibitors in solution unless compatibility has been verified by HPLC forced-degradation studies. Compliance with residue and withdrawal periods is determined by the finished dosage form and target species, not by the API alone.